ProfileGDS5678 / 1428120_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 59% 46% 59% 61% 65% 56% 59% 60% 56% 58% 54% 57% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5355458
GSM967853U87-EV human glioblastoma xenograft - Control 23.5205359
GSM967854U87-EV human glioblastoma xenograft - Control 33.0873746
GSM967855U87-EV human glioblastoma xenograft - Control 43.4723759
GSM967856U87-EV human glioblastoma xenograft - Control 53.6026161
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9793465
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5153856
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5235159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.587460
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3772356
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5123758
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2992354
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.460857
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5969660